These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 19771777)

  • 1. ["There are clear criteria for product surveillance studies"].
    Throm S
    MMW Fortschr Med; 2009 Aug; 151(34-35):7. PubMed ID: 19771777
    [No Abstract]   [Full Text] [Related]  

  • 2. [Surveillance studies criticized. A marketing effort for expensive drugs? "Not throwing the baby out with the bath water" (interview by Dr. Beate Schumacher)].
    Selbmann HK
    MMW Fortschr Med; 2009 Aug; 151(34-35):6. PubMed ID: 19771776
    [No Abstract]   [Full Text] [Related]  

  • 3. [Physician and pharmaceutical industry. II. Postmarketing surveillance].
    Offerhaus L
    Ned Tijdschr Geneeskd; 1992 Jan; 136(1):36-41. PubMed ID: 1728761
    [No Abstract]   [Full Text] [Related]  

  • 4. [Detection of side effects. 2: Responsibilities of the pharmaceutical industry, drug commissions, the Federal Health Office and international organizations].
    Gleiter CH; Bieck PR
    Fortschr Med; 1991 Jul; 109(21):429-31. PubMed ID: 1916572
    [No Abstract]   [Full Text] [Related]  

  • 5. Potential role of postmarketing research.
    Venulet J
    Drugs Exp Clin Res; 1987; 13(11):673-83. PubMed ID: 3443043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Responsibility of the pharmaceutical industry toward the first undesirable effects of new products].
    Juillet Y; de Cremiers F
    Therapie; 1988; 43(5):385-8. PubMed ID: 3227498
    [No Abstract]   [Full Text] [Related]  

  • 7. An underrecognized challenge in evaluating postmarketing drug safety.
    Roden DM
    Circulation; 2005 Jan; 111(3):246-8. PubMed ID: 15668350
    [No Abstract]   [Full Text] [Related]  

  • 8. Possible strategies for early recognition of potential drug safety problems.
    Venulet J
    Adverse Drug React Acute Poisoning Rev; 1988; 7(1):39-47. PubMed ID: 3389236
    [No Abstract]   [Full Text] [Related]  

  • 9. Post-marketing surveillance of drugs.
    Bell KD
    Med J Aust; 1991 Apr; 154(8):567. PubMed ID: 2064665
    [No Abstract]   [Full Text] [Related]  

  • 10. Strategy for surveillance of adverse drug events.
    Bright RA
    Food Drug Law J; 2007; 62(3):605-16. PubMed ID: 17915403
    [No Abstract]   [Full Text] [Related]  

  • 11. European commission consultation on pharmacovigilance.
    Waller P; Beard K; Egberts T; Evans S; Hallas J; Hasford J; Laporte JR; Moore N; Shakir S; Sturkenboom M
    Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):108-9. PubMed ID: 18058839
    [No Abstract]   [Full Text] [Related]  

  • 12. Collection and analysis of drug safety data in pregnancy.
    Moretti M
    Can J Clin Pharmacol; 2007; 14(1):e34-6. PubMed ID: 17213508
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmaceutical postmarket review: fact or fiction?
    Schanz SJ
    Food Drug Law J; 2007; 62(3):493-500. PubMed ID: 17915391
    [No Abstract]   [Full Text] [Related]  

  • 14. [Surveillance of drug use--pros and cons].
    Bruhn C
    Dtsch Med Wochenschr; 2009 Aug; 134(33):p29. PubMed ID: 19705346
    [No Abstract]   [Full Text] [Related]  

  • 15. Measuring adverse drug reactions in a postmarketing surveillance system.
    Fisher S; Bryant SG; Kluge RM
    Psychopharmacol Bull; 1986; 22(1):272-7. PubMed ID: 3726073
    [No Abstract]   [Full Text] [Related]  

  • 16. [Comprehensive detection of severe, potentially life-threatening drug side effects].
    Schönhöfer PS; Wessely-Stickel B; Schulte-Sasse H; Werner W
    Verh Dtsch Ges Inn Med; 1989; 95():687-90. PubMed ID: 2603504
    [No Abstract]   [Full Text] [Related]  

  • 17. European drug agency criticises Roche for failing to report adverse reactions and patient deaths.
    Wise J
    BMJ; 2012 Jun; 344():e4344. PubMed ID: 22736470
    [No Abstract]   [Full Text] [Related]  

  • 18. Development of a framework for enhancing the transparency, reproducibility and communication of the benefit-risk balance of medicines.
    Coplan PM; Noel RA; Levitan BS; Ferguson J; Mussen F
    Clin Pharmacol Ther; 2011 Feb; 89(2):312-5. PubMed ID: 21160469
    [No Abstract]   [Full Text] [Related]  

  • 19. Statewide test of a new postmarketing drug surveillance system.
    Fisher S; Bryant SG; Solovitz BL; Kluge RM
    Tex Med; 1987 Aug; 83(8):59-62. PubMed ID: 3660262
    [No Abstract]   [Full Text] [Related]  

  • 20. [Detection of drug side effects at the Heidelberg Medical Clinic].
    Jacubeit T; Drisch D
    Verh Dtsch Ges Inn Med; 1989; 95():690-3. PubMed ID: 2603505
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.